← Back to Clinical Trials
Recruiting Phase 2 NCT06831916

Impact of Cannabinoids on Menopause Symptoms

Trial Parameters

Condition Perimenopause
Sponsor Washington State University
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 100
Sex FEMALE
Min Age 40 Years
Max Age 60 Years
Start Date 2025-03-03
Completion 2027-01-12
Interventions
Active Cannabinoid ProductPlacebo

Brief Summary

The purpose of the study is to examine the impact of the hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.

Eligibility Criteria

Inclusion Criteria: * designated female at birth * 40-60 years of age * able to give informed consent (no intellectual disability) * stable pharmacotherapeutic regimen, no change in the past 3 months * abstinent from regular cannabis use (\<1x/month) for past year, and willing to abstain from use for 3 months * abstinent for supplements, don't add any supplements (no changes in past 3 months) * own a smartphone * have access to Zoom on a secure, stable internet connection * perimenopausal or menopausal Exclusion Criteria: * currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication * severe depression, neurovegetative symptoms, or current suicidality * psychosis or family history of psychosis * pregnant or breastfeeding * chemotherapy * hypotension * drug testing for work or other reasons * illicit drug use in past 3 months (cannabis not illicit) * heavy alcohol use (4 drinks more than 4x/week) * international/air travel planned for more than one week in the next 3

Related Trials